Provided is a combination of at least one CRTH2 antagonist and at least one proton pump inhibitor. Preferred CRTH2 antagonists are indole-alkanecarboxylic acid derivative compounds of general formula (I), wherein the variables are as defined in the specification. An example of a compound of formula (I) is (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid. Preferred proton pump inhibitors are selected from omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole. The combination is useful in the treatment of eosinophilic esophagitis.
